Do severe systemic sequelae of proteinuria modulate the antiproteinuric response to chronic ACE inhibition?

Nephrology Dialysis Transplantation

Volumn 17, Issue 5, 2002, Pages 793-797

  Bos, Hendrik ^a,b   Henning, Robert H ^a   De Jong, Paul E ^b   De Zeeuw, Dick ^a,b   Navis, Gerjan ^a,b,c  

^a Department of Clinical Pharmacology ^*  (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Established adriamycin nephrosis; Lisinopril; Plasma cholesterol; Proteinuria; Residual proteinuria; Systemic nephrosis

Indexed keywords

CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; LISINOPRIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CHOLESTEROL BLOOD LEVEL; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG RESPONSE; KIDNEY INJURY; MALE; MULTIVARIATE ANALYSIS; NEPHROSIS; NEPHROTIC SYNDROME; NONHUMAN; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; PROTEINURIA; RAT STRAIN;

EID: 0036097709     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/17.5.793     Document Type: Article

References (34)

1. Antiproteinuric effect predicts renal protection by angiotensin-converting enzyme inhibition in rats with established adriamycin nephrosis
2. Differential effects of enalapril and atenolol on proteinuria and renal haemodynamics in non-diabetic renal disease
3. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: A meta-analysis of randomized trials
4. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril
5. Systemic factors are involved in the pathogenesis of proteinuria-induced glomerulosclerosis in adriamycin nephrotic rats
6. Renal apolipoproteins in nephrotic rats
7. Dose of doxorubicin determines severity of renal damage and responsiveness to ACE-inhibition in experimental nephrosis
8. Chronic angiotensin II infusion but not bradykinin blockade abolishes the antiproteinuric response to angiotensin-converting enzyme inhibition in established adriamycin nephrosis
9. New insights into lipid metabolism in the nephrotic syndrome
10. Effects of delayed treatment with enalapril and/or lovastatin on the progression of glomerulosclerosis in 5/6 nephrectomized rats
11. Distinct and combined vascular effects of ACE blockade and HMG-CoA reductase inhibition in hypertensive subjects
12. Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril)
13. Beneficial effect of a multidrug approach in a severe rat model of disease progression resistant to ACE inhibitor alone
14. Pleiotropic effects of statins
15. Moderate sodium restriction in hypertensive subjects: Renal effects of ACE-inhibition
16. Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency
17. The role of lipids in renal disease: Future challenges
18. Cholesterol feeding following unilateral nephrectomy in the rat leads to glomerular hypertrophy
19. Cholesterol, macrophages and gene expression of TGF-beta 1 and fibronectin during nephrosis
20. Early glomerular changes in rats with dietary-induced hypercholesterolemia
21. Mechanisms of glomerular macrophage infiltration in lipid-induced renal injury
22. Mechanisms of progression of chronic renal damage
23. Antiproteinuric efficacy of fosinopril after renal transplantation is determined by the extent of vascular and tubulointerstitial damage
24. Effect of angiotensin converting enzyme inhibition by perindopril on proteinuria of primary renal diseases
25. Additive antiproteinuric effect of ACE inhibition and a low-protein diet in human renal disease
26. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria
27. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy
28. Long-term beneficial effects of angiotensin-converting enzyme inhibition in patients with nephrotic proteinuria
29. Evidence that an angiotensin-converting enzyme inhibitor has a different effect on glomerular injury according to the different phase of the disease at which the treatment is started
30. Effects of dietary protein restriction on the progression of moderate renal disease in the Modification of Diet in Renal Disease Study
31. ACE inhibition induces regression of proteinuria and halts progression of renal damage in a genetic model of progressive nephropathy
32. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease
33. Remission achieved in chronic nephropathy by a multidrug approach targeted at urinary protein excretion